<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">University of Birmingham Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">R</forename><surname>Libé</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">French Adrenal Cancer Network</orgName>
								<orgName type="department" key="dep2">Institut National du Cancer</orgName>
								<address>
									<settlement>Paris</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Borget</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Biostatistics and Epidemiology</orgName>
								<orgName type="institution">Gustave Roussy and University Paris-Sud</orgName>
								<address>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ronchi</surname></persName>
							<affiliation key="aff2">
								<orgName type="laboratory">Central Laboratory, Research Unit</orgName>
								<orgName type="institution">University Hospital Wurzburg</orgName>
								<address>
									<settlement>Wurzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Zaggia</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution" key="instit1">San Luigi Hospital</orgName>
								<orgName type="institution" key="instit2">University of Turin</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Kroiss</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Comprehensive Cancer Center Mainfranken</orgName>
								<orgName type="institution">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Kerkhofs</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution">Maxima Medisch Centrum</orgName>
								<address>
									<settlement>Eindhoven</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Bertherat</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Endocrinology Unit</orgName>
								<orgName type="institution">Cochin Hospital</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Volante</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">University of Turin</orgName>
								<orgName type="institution" key="instit2">San Luigi Hospital</orgName>
								<address>
									<settlement>Turin</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Quinkler</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Clinical Endocrinology</orgName>
								<orgName type="department" key="dep2">10 Endocrinology Unit</orgName>
								<orgName type="institution" key="instit1">Charit Campus Mitte</orgName>
								<orgName type="institution" key="instit2">Charitί University Medicine Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">University Hospital of Grenoble</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">O</forename><surname>Chabre</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Bala</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrine and Diabetes Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital Würzburg</orgName>
								<orgName type="institution" key="instit2">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Tabarin</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Endocrinology</orgName>
								<orgName type="institution" key="instit1">CHU Bordeaux</orgName>
								<orgName type="institution" key="instit2">University of Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Beuschlein</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Klinikum</orgName>
								<orgName type="institution" key="instit1">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution" key="instit2">Ludwig-Maximilians-Universität München</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Vezzosi</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Endocrinology and Metabolic Diseases</orgName>
								<orgName type="institution">CHU Larrey</orgName>
								<address>
									<settlement>Toulouse</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Deutschbein</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrine and Diabetes Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital Würzburg</orgName>
								<orgName type="institution" key="instit2">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Borson-Chazot</surname></persName>
							<affiliation key="aff14">
								<orgName type="laboratory">Nuclear Medicine Unit</orgName>
								<orgName type="institution">University of Lyon 1</orgName>
								<address>
									<settlement>Hospices Civils de Lyon Bron</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Hermsen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution">Maxima Medisch Centrum</orgName>
								<address>
									<settlement>Eindhoven</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Stell</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Melbourne eResearch Group Level 3</orgName>
								<orgName type="department" key="dep2">Doug McDonell Building</orgName>
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Fottner</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Medicine 1</orgName>
								<orgName type="institution" key="instit1">University Medical Center</orgName>
								<orgName type="institution" key="instit2">Johannes Gutenberg-University Mainz</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Leboulleux</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Nuclear Medicine and Endocrine Tumors</orgName>
								<orgName type="institution">Institut Gustave Roussy</orgName>
								<address>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Hahner</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrine and Diabetes Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital Würzburg</orgName>
								<orgName type="institution" key="instit2">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Mannelli</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Experimental and Clinical Biomedical Sciences &apos;Mario Serio&apos;</orgName>
								<address>
									<settlement>Florence</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Department of Medical and Surgical Specialties</orgName>
								<orgName type="department" key="dep2">Radiological Sciences and Public Health</orgName>
								<orgName type="institution" key="instit1">University of Brescia</orgName>
								<orgName type="institution" key="instit2">Spedali Civili Hospital</orgName>
								<address>
									<settlement>Brescia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Haak</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution">Maxima Medisch Centrum</orgName>
								<address>
									<settlement>Eindhoven</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Terzolo</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Internal Medicine</orgName>
								<orgName type="institution" key="instit1">San Luigi Hospital</orgName>
								<orgName type="institution" key="instit2">University of Turin</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="laboratory">Endocrine and Diabetes Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital Würzburg</orgName>
								<orgName type="institution" key="instit2">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Eric</forename><surname>Baudin</surname></persName>
							<email>eric.baudin@gustaveroussy.fr</email>
							<affiliation key="aff17">
								<orgName type="department">Department of Nuclear Medicine and Endocrine Tumors</orgName>
								<orgName type="institution">Institut Gustave Roussy</orgName>
								<address>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Yago</forename><surname>Nieto</surname></persName>
							<email>ynieto@mdanderson.org</email>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">Department of Nuclear Medicine and Endocrine Tumors</orgName>
								<orgName type="institution">Institut Gustave Roussy</orgName>
								<address>
									<addrLine>39 rue Camille Desmoulins</addrLine>
									<postCode>94805</postCode>
									<settlement>Villejuif Cedex</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department">Department of Stem Cell Transplantation and Cellular Therapy</orgName>
								<orgName type="institution">University of Texas MD Anderson Cancer Center</orgName>
								<address>
									<addrLine>1515 Holcombe Blvd, Unit 423</addrLine>
									<postCode>77030</postCode>
									<settlement>Houston</settlement>
									<region>TX</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">University of Birmingham Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6814D0677F1F51831552AB4D32A0A448</idno>
					<idno type="DOI">10.1093/annonc/mdv329</idno>
					<note type="submission">Received 10 February 2015; revised 16 June 2015 and 17 July 2015; accepted 24 July 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:36+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>adrenocortical carcinoma</term>
					<term>prognostic factors</term>
					<term>ENSAT</term>
					<term>GRAS bevacizumab</term>
					<term>gemcitabine</term>
					<term>docetaxel</term>
					<term>high-dose chemotherapy</term>
					<term>autologous transplantation</term>
					<term>germ-cell tumors</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background:</head><p><s>The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous.</s><s>Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.</s></p><p><s>Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled.</s><s>The primary end point was overall survival (OS).</s><s>Parameters of potential prognostic relevance were selected.</s><s>Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.</s></p><p><s>Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed.</s></p><p><s>After a median follow-up of 55.2 months, the median OS was 24 months.</s><s>A modified ENSAT (mENSAT) classification was validated: stage III (invasion of surrounding tissues/organs or the vena renalis/cava) and stage IVa, IVb, IVc (2, 3 or &gt;3 metastatic organs, including N, respectively).</s><s>Two-or 5-year OS was 73%, 46%, 26% and 15% or 50%, 15%, 14% and 2% for stages III, IVa, IVb and IVc, respectively.</s><s>In the multivariate analysis, mENSAT stages (stages IVa, IVb, or IVc, respectively) were significantly correlated with OS (P &lt; 0.0001), as well as additional parameters: age ≥50 years (P &lt; 0.0001), tumor-or hormone-related symptoms (P = 0.01 and 0.03, respectively) in model 1 but also the R status (P = 0.001) and Grade (Weiss &gt;6 and/or Ki67 ≥20%, P = 0.06) in model 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>The mENSAT classification and GRAS parameters (Grade, R status, Age and Symptoms) were found to best stratify the prognosis of patients with advanced ACC.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>• Users may freely distribute the URL that is used to identify this publication.</s></p><p><s>• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.</s></p><p><s>• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.</s></p><p><s>Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.</s></p><p><s>When citing, please reference the published version.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Take down policy</head><p><s>While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.</s><s><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b3">[3]</ref><ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref>.</s><s>Treatment options for such patients are limited <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b9">9]</ref>, and no predictors of response have been validated.</s><s>The best way to stratify the prognosis of advanced ACC continues to fuel debate.</s><s>Indeed, several studies suggest that patients with stage III disease and positive lymph nodes (N1) or vena cava invasion could have a similar prognosis to that of those with stage IV disease <ref type="bibr" target="#b7">[7,</ref><ref type="bibr" target="#b10">10,</ref><ref type="bibr" target="#b11">11]</ref>.</s><s>The number of tumor-involved organs in patients with stage IV ACC has been reported to be useful for refining the prognosis of these patients as well <ref type="bibr" target="#b12">[12]</ref>.</s><s>Furthermore, several studies also claim that age, hormone secretion, the Weiss score and/or proliferative index and the resection (R) status may also exert an impact on the prognosis of these patients <ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref>. Better prognostic stratification is therefore needed in advanced ACC <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b9">9]</ref>.</s></p><p><s>The objective of this retrospective study was to refine the prognostic classification of patients with advanced stage III and stage IV ACC at diagnosis.</s><s>To achieve this goal, the ENSAT registry, comprising a large number of ACC patients treated in expert centers in four European countries, was utilized.</s><s>Data collected included: age, sex, modality of tumor diagnosis [defined as : incidental, symptom-related either to the tumor mass (i.e.</s><s>abdominal pain) or hormone secretions (glucocorticoids, mineralocorticoids, androgens hypersecretion) or other/unknown], ENSAT or UICC TNM classifications (tumor size, invasion of adjacent tissue/organs or vena cava/renalis vein, lymph node or distant metastases), involved organs, tumor grade based on the pathological analysis of the primary tumor [defined as the Weiss score (≤6/&gt;6) or Ki67 percentage (&lt;20%/≥20%)], the R status at first surgery (complete resection:R0; microscopic residual disease:R1; macroscopic residual disease:R2, resection not-known: Rx).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patient and data collection</head><p><s>The ENSAT registry was approved by the local ethics committees of all participating centers and all patients included had given their written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>evaluation of different stage III-IV definitions and tumor grading systems</head><p><s>In order to validate the best way to stratify the TNM classification of advanced ACC patients, four different TNM classification systems were compared before the final prognostic analysis: the UICC, ENSAT and two proposed modified ENSAT classifications (mENSAT).</s></p><p><s>The two mENSAT classifications were constructed as described in supplementary Figure <ref type="figure" target="#fig_2">S1A and B</ref>, available at Annals of Oncology online by analyzing independently the prognostic influence of N status and venous invasion.</s><s>In addition, stage IV was categorized into subgroups according to the number of tumor-involved organs (IVa: 2, IVb: 3, IVc: &gt;3 organs).</s></p><p><s>In order to classify the tumor grade, three different classifications were analyzed as described in supplementary Figure <ref type="figure">S2A-C</ref>, available at Annals of Oncology online, by analyzing the prognostic influence of the Weiss score, Ki67 or a combination of both parameters.</s></p><p><s>Patients whose Weiss score and Ki67 were both missing, as well as patients who have no adrenalectomy, were excluded from the analysis.</s></p><p><s>Parameter selection and combinations were carried out graphically, using the Kaplan-Meier and the Hall-Wellner confidence intervals of each curve.</s><s>The parameters considered to best reflect the tumor burden and the tumor grade were those allowing the greatest discrimination of patients in terms of overall survival (OS), graphically.</s><s>statistics Descriptive analyses were carried out using means and standard deviations for quantitative variables, and comparisons were carried out using the Student test (or non-parametric Wilcoxon test if non-normally distributed).</s><s>Qualitative variables were expressed as percentages and comparisons were carried out using the χ 2 test.</s></p><p><s>The primary end point was OS, defined as the interval between the date of the diagnosis of stage III or IV ACC and death due to any cause.</s><s>Surviving patients were censored at the date of the last follow-up.</s><s>Follow-up data were last updated in November 2012.</s><s>The median follow-up was estimated by the reverse Kaplan-Meier method (Schemper's method).</s></p><p><s>Survival rates and 95% confidence intervals were estimated by the Kaplan-Meier method.</s><s>The log-rank test was used to compare survival curves.</s><s>The parameters significantly associated with OS in the univariate analysis (P &lt; 0.05) were further tested in the multivariate analysis.</s><s>Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox's proportional hazards regression model in the multivariate analysis, with the lowest risk group as the reference group.</s><s>All tests were two sided.</s></p><p><s>Variables, as well as cut-off thresholds, are presented in supplementary Table <ref type="table" target="#tab_1">S1</ref>, available at Annals of Oncology online: they were analyzed for their potential prognostic value in the univariate analysis.</s></p><p><s>Two multivariate analyses were carried out: model 1 (before-surgery) analyzed all prognostic parameters available at the time of ACC diagnosis.</s><s>Model 2 ( post-surgery) analyzed all prognostic parameters including the pathological grade and R status in patients who underwent adrenalectomy.</s><s>The statistical analysis was conducted using SAS software version 9.2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>results population characteristics and follow-up data</head><p><s>Four hundred and sixty-three cases were reviewed: 15 were excluded because &lt;18 years old and 4 because lost at follow-up.</s><s>Thus, 444 patients constituted the study population: 210 (47%) were ENSAT stage III and 234 (53%) stage IV.</s><s>The main population characteristics are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>Supplementary Table <ref type="table" target="#tab_2">S2</ref>, available at Annals of Oncology online describes the different treatments received by the patients during the first year of therapy.</s><s>Patients with stage III underwent significantly more frequently surgery than those with stage IV: no surgery was carried out in 6 ENSAT stage III patients and in 54 ENSAT stage IV patients.</s></p><p><s>The median follow-up of patients was 55.2 (range 0-139) months.</s><s>The median OS was 24 (21.6-27.7)</s><s>months.</s><s>The 2and 5-year survival rates were 50% (CI 45%-55%) and 27% (CI 23%-31%), respectively.</s><s>selection of the best TNM and pathology classifications in advanced ACC patients N-positive status but not venous invasion outcome was found to overlap with stage IV outcome (supplementary Figure <ref type="figure" target="#fig_2">S1A</ref> and B, available at Annals of Oncology online).</s><s>Therefore, the first mENSAT classification was considered to better stratify the prognosis of patients with stage III-IV ACC.</s><s>It defined stage III as T3-4N0M0 and stage IVa, IVb, IVc according to the number of tumor-involved organs (including the primary tumor and the 'N' as 'organ'): 2, 3 or &gt;3, respectively (supplementary Table <ref type="table">S3</ref>, available at Annals of Oncology online).</s><s>ENSAT and mENSAT classifications were found to be more informative than their UICC counterpart (Figure <ref type="figure" target="#fig_2">1A-C</ref>).</s></p><p><s>Regarding pathological grading, prognostic information but also the number of available data were taken into account.</s><s>Both Ki67 and the Weiss score significantly discriminated OS outcome in the univariate analysis.</s><s>However, Ki67 had not been documented in a significant number of patients.</s><s>The Weiss score and/or Ki67 were available in 340 patients and the combination of the two pathological parameters allowed us to significantly discriminate two subgroups of patients, in terms of OS (supplementary Figure <ref type="figure">S2A-C</ref>, available at Annals of Oncology online) and to apply this pathological classification.</s></p><p><s>prognostic factors for OS univariate analysis.</s><s>In the univariate analysis, the following parameters were significantly inversely associated with OS: age ≥50 years, tumor or hormone-related symptoms at diagnosis, ENSAT, mENSAT classification, the R status, Weiss score &gt;6 and Ki67 ≥20% (supplementary Table <ref type="table" target="#tab_1">S1</ref>, available at Annals of Oncology online).</s></p><p><s>In the mENSAT classification, stage III, IVa, IVb and IVc were significantly associated with OS.</s><s>In particular, the median OS in stage III, IVa, IVb and IVc was 60.8 (CI 39.8-81.5),</s><s>21.2 (CI 15.7-25.9),</s><s>12.1 (CI 9.4-14.9)</s><s>and 13.6 (CI 8.6-15.8)</s><s>months, respectively.</s><s>Specifically, 2-year OS was 73% (CI 66%-79%), 46% (CI 37%-54%), 26% (CI 16%-37%) and 15% (CI 7%-25%) for stages III, IVa, IVb and IVc and 5-year OS was 50% (CI 44%-60%), 15% (CI 8%-22%), 14% (CI 6%-24%) and 2% (CI 0.01%-9%) for stages III, IVa, IVb and IVc, respectively.</s><s>multivariate analysis: models 1 and 2. In the multivariate analysis (model 1), the following parameters were significantly and independently associated with an increased risk of death: age ≥50 years (P &lt; 0.0001), tumor-or hormone-related symptoms (P = 0.01, 0.03, respectively), the mENSAT stage (all P &lt; 0.0001) (Table <ref type="table" target="#tab_2">2</ref>).</s><s>When Nx patients were excluded or considered as a separate subgroup, the results remained unchanged.</s><s>With model 2, the following parameters were significantly associated with an increased risk of death: age ≥50 years (P &lt; 0.04), tumor-related symptoms (P = 0.01), the mENSAT stages (all P &lt; 0.0001) and the R status (P = 0.001).</s><s>The HR of the tumor grade (Weiss &gt;6 and/or Ki67 ≥20%) reached 1.3 and the hormone-related symptoms at diagnosis was 1.5, with a P-value that tended to be significant for both variables (P = 0.06).</s><s>When Rx patients were excluded or considered as a separate subgroup, the results remained unchanged.</s></p><p><s>In the following section, the acronym 'GRAS', used to designate Grading (G), the R status (R), Age (A) and Symptoms (S), defined as tumor-or hormone-related symptoms at diagnosis, corresponds to these parameters.</s><s>combining prognostic parameters.</s><s>We then attempted to refine the prognostic classification of ACC by combining the mENSAT stage with the GRAS parameters.</s><s>Age ≥50 years and/or presence of symptoms were first combined with mENSAT stages III and IVa in model 1 (Figure <ref type="figure">2A and B</ref>).</s><s>Unfavorable grading or the R status was subsequently combined with the same mENSAT stages in model 2 (Figure <ref type="figure">3A and B</ref>).</s></p><p><s>Figures <ref type="figure">2 and 3</ref> show that these GRAS parameters significantly affect the prognosis of mENSAT stage III or IVa.</s><s>Fiveyear OS of mENSAT stage III was 50% but ranged from 68%, for age &lt;50 years and an incidental tumor (Figure <ref type="figure">2A</ref>) in model 1 to 22% when tumor grading and the R status were unfavorable in model 2 (Figure <ref type="figure">3A</ref>).</s></p><p><s>Five-year OS of mENSAT stage IVa was 15% but ranged from 0% to 55% when age and functional symptoms were unfavorable or favorable in model 1 (Figure <ref type="figure">2B</ref>), respectively, and ranged from 16% to 46% when tumor grading and the R status were unfavorable or favorable in model 2 (Figure <ref type="figure">3B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>discussion</head><p><s>This collaborative study of the ENSAT network allowed us to refine the prognostic classification in a large and typical group of patients with advanced ACC defined as stage III or synchronous stage IV disease <ref type="bibr" target="#b3">[3,</ref><ref type="bibr" target="#b5">5,</ref><ref type="bibr" target="#b12">12]</ref>.</s><s>We propose a new mENSAT TNM classification and confirm the prognostic value of four additional prognostic parameters named 'GRAS' parameters.</s></p><p><s>The tumor stage, best defined by the mENSAT classification, was confirmed as the keystone of the prognostic stratification.</s><s>We investigated the prognostic role of the N status together with venous invasion and we found that the N1 status plays a deleterious prognostic role comparable to stage IV ACC, as previously  reported <ref type="bibr" target="#b7">[7,</ref><ref type="bibr" target="#b10">10]</ref>.</s><s>In addition, we confirmed the prognostic value of the number of tumor-involved organs, including the primary and lymph node involvement <ref type="bibr" target="#b12">[12]</ref>.</s><s>On the basis of these results, we created a new prognostic TNM classification restricted to patients with advanced ACC, the mENSAT stage III-IV classification, which allowed us to unambiguously discriminate the prognostic outcomes of four categories of patients namely, stage III, IVa, IVb and IVc with 5-year OS rates of 50%, 15%, 14% and 2%, respectively.</s><s>In this new classification, the N1 status shifts tumors from ENSAT stage III to the mENSAT stage IV category (i.e.</s><s>IVa, if the N1 is isolated).</s><s>In contrast, the prognosis of ACC with venous invasion was found to be comparable to that of other subgroups of stage III N0 disease.</s><s>However, a limitation of our study is the fact that vena cava or vena renalis invasion was not accurately documented in all cases <ref type="bibr" target="#b5">[5]</ref>.</s><s>Furthermore, it should be borne in mind that the N classification used in our study refers to both imaging and pathological classifications and future refinements are expected.</s><s>These results may suggest that surgical excision of the ACC primary tumor including venous invasion is better handled by ACC surgeons than lymph node dissection whose putative role has only been underlined recently <ref type="bibr" target="#b11">[11,</ref><ref type="bibr" target="#b18">18]</ref>.</s><s>In addition to the mENSAT classification, we validated for the first time, after optimization and adjustment for the tumor burden in advanced ACC, four additional prognostic parameters, designated GRAS, that were found to affect the prognosis of each mENSAT stage.</s></p><p><s>Indeed, 5-year OS of stage III patients ranged between 60% and 70% in patients &lt;50 years-old with an incidentally discovered ACC or with an R0 status and favorable tumor grading but dropped to 22% when the tumor grade and the R status were both found to be unfavorable.</s><s>Five-year OS for patients with stage IVa disease was 15% but ranged from 0 to 55% in patients with favorable or unfavorable GRAS parameters, again suggesting an overlap between patients with stage III and IVa disease.</s><s>The validation of the precise prognostic roles of each parameter and the combination of GRAS parameters require additional studies in larger and independent group of patients to better understand the magnitude of their influence for each stage.</s><s>Meanwhile, standardization, including quantification when feasible, of the analysis of each prognostic parameter is required.</s></p><p><s>Age was expressed as a binomial parameter according to the median in this study which may be optimized.</s><s>Also future studies should investigate more precisely how far the magnitude and subtypes of secretions affect the prognosis <ref type="bibr" target="#b13">[13,</ref><ref type="bibr" target="#b15">15]</ref>.</s><s>The prognostic influence of the Weiss score in comparison to the Ki67 index, but also standardization of their analyses in all patients and comparisons of the informative value of the primary and metastasis require further studies.</s></p><p><s>The R0 status of the primary was identified as a major prognostic parameter in our study, suggesting that the benefit of the R0 status applies not only to stage III but also to stage IV.</s><s>However, the R status can be considered a surrogate for the tumor burden but also reflects the surgeon's expertise which is difficult to analyze objectively.</s><s>In addition, the best time to perform R0 resection remains to be more precisely defined.</s></p><p><s>The strengths of this study include the large number of patients based on national expert European networks together with prolonged follow-up allowing robust conclusions in this rare cancer.</s><s>The limitations of this study include its retrospective nature explaining the lack of consistency for pathological, R and N status reports.</s><s>In addition, as for all prognostic studies, the impact of therapeutic intervention was not analyzed which may affect the results.</s><s>Standardization and further validations of the mENSAT-GRAS parameters are however warranted in a prospective cohort of patients as well as the analysis of the added value of the recently published molecular classification of ACC patients <ref type="bibr" target="#b19">[19]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>conclusion</head><p><s>The mENSAT classification was found to best stratify the prognosis of advanced ACC patients.</s><s>After adjustment to the mENSAT classification, four additional prognostic 'GRAS' parameters were found.</s><s>Prospective validation of this new prognostic system is expected.</s><s>acknowledgements</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>From 1</head><label>1</label><figDesc><div><p><s>January 2000 to 31 December 2009, 463 patients with stage III or IV ACC followed up in 16 expert referral centers in four European countries (Germany, France, Italy and The Netherlands) were consecutively registered in the ENSAT ACC Registry.</s><s>Inclusion criteria were: a confirmed histological diagnosis of ACC, stage III-IV disease at imaging and/or surgery carried out within 3 months of the diagnosis, age &gt;18 years and available follow-up data.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Overall survival according to UICC (A), ENSAT (B) and m-ENSAT (C) TNM classifications in 444 advanced adrenocortical carcinoma patients.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>1 :</head><label>1</label><figDesc><div><p><s>Age &lt; 50 years and absence of symptoms 2:2:Age &lt; 50 years and presence of symptoms 3:3:Age &gt;= 50 years and absence of symptoms 4:4:Age &gt;= 50 years and presence of symptoms 1:1:Age &lt; 50 years and absence of symptoms 2:2:Age &lt; 50 years and presence of symptoms 3:3:Age &gt;= 50 years and absence of symptoms 4:4:Age &gt;= 50 years and presence of symptoms</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 .Figure 3 .</head><label>23</label><figDesc><div><p><s>Figure 2. Kaplan-Meier curves of overall survival according to age and the modality of the diagnosis (model 1) in mENSAT stage III (A) and stage IVa (B).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Clinical and pathological characteristics of 444 patients with advanced adrenocortical carcinoma</s></p></div></figDesc><table><row><cell>Parameters</cell><cell>n of patients (%)</cell><cell>n of assessable</cell></row><row><cell></cell><cell></cell><cell>patients</cell></row><row><cell>Patients</cell><cell>444</cell><cell>444</cell></row><row><cell>Age(years)</cell><cell></cell><cell></cell></row><row><cell>&lt;50</cell><cell>200 (45%)</cell><cell>444</cell></row><row><cell>≥50</cell><cell>244 (55%)</cell><cell></cell></row><row><cell>Gender</cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>173 (39%)</cell><cell>444</cell></row><row><cell>Female</cell><cell>271 (61%)</cell><cell></cell></row><row><cell>Modality of diagnosis</cell><cell></cell><cell></cell></row><row><cell>Tumor-related symptoms</cell><cell>163 (37%)</cell><cell>444</cell></row><row><cell>Hormone-related symptoms</cell><cell>144 (32%)</cell><cell></cell></row><row><cell>Incidentally</cell><cell>65 (15%)</cell><cell></cell></row><row><cell>Other/unknown</cell><cell>72 (16%)</cell><cell></cell></row><row><cell>ENSAT stage</cell><cell></cell><cell></cell></row><row><cell>III</cell><cell>210 (48%)</cell><cell>444</cell></row><row><cell>IV</cell><cell>234 (52%)</cell><cell></cell></row><row><cell>Modified ENSAT stage (mENSAT)</cell><cell></cell><cell></cell></row><row><cell>III</cell><cell>177 (40%)</cell><cell>444</cell></row><row><cell>IVa</cell><cell>139 (31%)</cell><cell></cell></row><row><cell>IVb</cell><cell>65 (15%)</cell><cell></cell></row><row><cell>IVc</cell><cell>63 (14%)</cell><cell></cell></row><row><cell>Tumor (T)</cell><cell></cell><cell></cell></row><row><cell>T1</cell><cell>11 (2%)</cell><cell>444</cell></row><row><cell>T2</cell><cell>97 (22%)</cell><cell></cell></row><row><cell>T3</cell><cell>140 (32%)</cell><cell></cell></row><row><cell>T4</cell><cell>196 (44%)</cell><cell></cell></row><row><cell>Regional lymph nodes (N1)</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>98 (22%)</cell><cell>444</cell></row><row><cell>N</cell><cell>202 (45%)</cell><cell></cell></row><row><cell>Unknown</cell><cell>144 (32%)</cell><cell></cell></row><row><cell>Organ metastases (M1)</cell><cell></cell><cell></cell></row><row><cell>Lung</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>152 (34%)</cell><cell>444</cell></row><row><cell>N</cell><cell>292 (65%)</cell><cell></cell></row><row><cell>Liver</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>125 (28%)</cell><cell>444</cell></row><row><cell>N</cell><cell>319 (72%)</cell><cell></cell></row><row><cell>Bone</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>32 (7%)</cell><cell>444</cell></row><row><cell>N</cell><cell>412 (93%)</cell><cell></cell></row><row><cell>Adrenalectomy</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>384 (86%)</cell><cell>444</cell></row><row><cell>N</cell><cell>60 (14%)</cell><cell></cell></row><row><cell>R status in resected patients</cell><cell></cell><cell></cell></row><row><cell>R0 a</cell><cell>150 (39%)</cell><cell>384</cell></row><row><cell>R1</cell><cell>34 (9%)</cell><cell></cell></row><row><cell>R2</cell><cell>91 (24%)</cell><cell></cell></row><row><cell>Rx</cell><cell>109 (28%)</cell><cell></cell></row><row><cell>Weiss score</cell><cell></cell><cell></cell></row><row><cell>≤ 6</cell><cell>174 (53%)</cell><cell>327</cell></row><row><cell>&gt;6</cell><cell>153 (47%)</cell><cell></cell></row><row><cell>Ki 67 (%)</cell><cell></cell><cell></cell></row><row><cell>&lt;20</cell><cell>103 (46%)</cell><cell>226</cell></row><row><cell>≥ 20</cell><cell>123 (54%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Continued</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Continued</s></p></div></figDesc><table><row><cell>Parameters</cell><cell>n of patients (%)</cell><cell>n of assessable</cell></row><row><cell></cell><cell></cell><cell>patients</cell></row><row><cell>Death</cell><cell></cell><cell></cell></row><row><cell>Y</cell><cell>301 (68%)</cell><cell>444</cell></row><row><cell>N</cell><cell>143 (32%)</cell><cell></cell></row><row><cell>Alive</cell><cell></cell><cell></cell></row><row><cell>With disease or recurrence</cell><cell>76 (53%)</cell><cell>143</cell></row><row><cell>Without disease</cell><cell>63 (44%)</cell><cell></cell></row><row><cell>Unknown</cell><cell>4 (3%)</cell><cell></cell></row></table><note><p><s>a Primary including metastases in 43 patients.</s><s>Volume 26 | No. 10 | October 2015 doi:10.1093/annonc/mdv329</s><s>| </s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Multivariate analyses (models 1 and 2)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Model 1 (n = 444 patients)</cell><cell></cell><cell cols="2">Model 2 (n = 340 patients)</cell><cell></cell></row><row><cell></cell><cell>Hazard ratio</cell><cell>95% CI</cell><cell>P-value</cell><cell>Hazard ratio</cell><cell>95% CI</cell><cell>P-value</cell></row><row><cell>Age</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;50 years</cell><cell>1</cell><cell>1</cell><cell></cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>≥50 years</cell><cell>1.6</cell><cell>1.3-2.1</cell><cell>&lt;0.0001</cell><cell>1.3</cell><cell>1.01-1.8</cell><cell>0.04</cell></row><row><cell>Modality of diagnosis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Incidentally</cell><cell>1</cell><cell>1</cell><cell></cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>Tumor mass</cell><cell>1.7</cell><cell>1.1-2.5</cell><cell>0.01</cell><cell>1.8</cell><cell>1.1-2.8</cell><cell>0.01</cell></row><row><cell>Hormone hypersecretion</cell><cell>1.6</cell><cell>1.05-2.4</cell><cell>0.03</cell><cell>1.5</cell><cell>0.97-2.5</cell><cell>0.06</cell></row><row><cell>Other or unknown</cell><cell>1.2</cell><cell>0.8-1.9</cell><cell>0.40</cell><cell>1.05</cell><cell>0.6-1.8</cell><cell>0.83</cell></row><row><cell>Modified ENSAT stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>III</cell><cell>1</cell><cell>1</cell><cell></cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>IVa</cell><cell>2.6</cell><cell>2.0-3.5</cell><cell>&lt;0.0001</cell><cell>2.1</cell><cell>1.5-2.9</cell><cell>&lt;0.0001</cell></row><row><cell>IVb</cell><cell>3.6</cell><cell>2.5-5.1</cell><cell>&lt;0.0001</cell><cell>2.4</cell><cell>1.5-3.7</cell><cell>&lt;0.0001</cell></row><row><cell>IVc</cell><cell>5.1</cell><cell>3.6-7.3</cell><cell>&lt;0.0001</cell><cell>4.3</cell><cell>2.7-6.5</cell><cell>&lt;0.0001</cell></row><row><cell>Tumor grade</cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Weiss ≤6 and Ki &lt;20</cell><cell></cell><cell></cell><cell></cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>Weiss &gt;6 and or Ki ≥20</cell><cell></cell><cell></cell><cell></cell><cell>1.3</cell><cell>0.99-1.7</cell><cell>0.06</cell></row><row><cell>R status</cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>R0</cell><cell></cell><cell></cell><cell></cell><cell>1</cell><cell>1</cell><cell></cell></row><row><cell>R 1, 2, X</cell><cell></cell><cell></cell><cell></cell><cell>1.6</cell><cell>1.2-2.2</cell><cell>0.001</cell></row></table><note><p><s>Model 1: prognostic model with clinical variables, without pathology and the R status; model 2: prognostic model with clinical variables, with pathology and the R status.</s><s>NA, not applicable.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Golden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Saldanha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1853" to="1878" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Kerkhofs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Verhoeven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Der Zwan</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="2579" to="2586" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group</title>
		<author>
			<persName><forename type="first">P</forename><surname>Icard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Goudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Charpenay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Surg</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="891" to="897" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Lughezzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perrotte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="713" to="719" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Johanssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quinkler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="243" to="250" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Schulick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brennan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="719" to="726" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Bilimoria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Elaraj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="3130" to="3136" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gelderblom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="131" to="138" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrinol Metab Clin North Am</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="411" to="434" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Prognosis of stage III adrenocortical carcinoma after radical resection: a French retrospective multicentric study from the COMETE Network</title>
		<author>
			<persName><forename type="first">Do</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leboulleux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Borget</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>European Congress of Endocrinology</publisher>
			<biblScope unit="page">70</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma: the influence of large vessel extension</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Turbendian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Strong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1057" to="1064" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>discussion 1064</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prognostic parameters of metastatic adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Assie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Antoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="148" to="154" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Abiven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Groussin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2650" to="2655" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification</title>
		<author>
			<persName><forename type="first">M</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bollito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sperone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="535" to="543" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="832" to="838" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Gauger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Hammer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Langenbecks Arch Surg</title>
		<imprint>
			<biblScope unit="volume">395</biblScope>
			<biblScope unit="page" from="955" to="961" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Adrenocortical carcinoma: clinical, morphologic, and molecular characterization</title>
		<author>
			<persName><forename type="first">A</forename><surname>Stojadinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Ghossein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="941" to="950" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Reibetanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jurowich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Erdogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">255</biblScope>
			<biblScope unit="page" from="363" to="369" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Integrated genomic characterization of adrenocortical carcinoma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Assie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Letouze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fassnacht</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdv310</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Oncology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="2125" to="2132" />
			<date type="published" when="2014">2014. 2015. July 2015</date>
		</imprint>
	</monogr>
	<note>Nat Genet. Published online 21</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Departments of 1 Stem Cell Transplantation and Cellular Therapy; 2 Genitourinary Medical Oncology</title>
		<imprint>
			<date type="published" when="2015-05-22">22 May 2015. July 2015. 10 July 2015</date>
			<biblScope unit="volume">5</biblScope>
			<pubPlace>University of Texas MD Anderson Cancer Center, Houston; Fred Hutchinson Cancer Research Center, Seattle, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Department of Medical Oncology</orgName>
		</respStmt>
	</monogr>
	<note>3 Biostatistics; 4 Pharmacy. revised 1</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">However, outcomes of high-risk patients in advanced relapse remain poor. We previously developed a new HDC regimen combining infusional gemcitabine with docetaxel/melphalan/carboplatin (GemDMC), with preliminary high activity in refractory GCT. Given the high vascular endothelial growth factor expression in metastatic GCT and the synergy between bevacizumab and chemotherapy, we studied concurrent bevacizumab and sequential HDC using GemDMC and ifosfamide/carboplatin/etoposide (ICE) in patients with poor-risk relapsed or refractory disease. Patients and methods: Eligibility criteria included intermediate/high-risk relapse</title>
	</analytic>
	<monogr>
		<title level="m">Background: High-dose chemotherapy (HDC) using sequential cycles of carboplatin/etoposide is curative for relapsed germ-cell tumors (GCT)</title>
				<imprint>
			<publisher>Beyer Model</publisher>
		</imprint>
	</monogr>
	<note>serum creatinine ≤1.8</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The trial was powered to distinguish a target 50% 2-year relapse-free survival (RFS) from an expected 25% 2-year RFS in this population. Results: We enrolled 43 male patients, median age 30 (20-49) years, with absolute refractory (N = 20), refractory (N = 17) or cisplatin-sensitive (N = 6) disease, after a median 3 (1-5) prior relapses. Disease status right before HDC was unresponsive (N = 24, progressive disease 22, stable disease 2), partial response with positive markers (PRm + ) (N = 8)</title>
	</analytic>
	<monogr>
		<title level="m">Patients received sequential HDC cycles with bevacizumab preceding GemDMC (cycle 1) and ICE</title>
				<imprint>
			<biblScope unit="volume">46</biblScope>
		</imprint>
	</monogr>
	<note>At median follow-up of. 9-84) months, the RFS and overall survival rates are 55.8% and 58.1%, respectively</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
